Natural Product Chemistry in Sickle Cell Disease Therapeutics: Phytochemical Mechanisms, Pharmacokinetics, and Computational Docking Insights for Next-Generation Anti-Sickling Agents: A Comprehensive Review

1. Introduction

Sickle cell disease (SCD) is the most common severe monogenic disorder in the world. According to the World Health Organization’s 2025 assessment, an estimated 7.74 million people were living with SCD globally as of 2021, with roughly 515,000 new births affected each year and approximately 81,100 deaths in children under five attributable to the disease directly — a figure that rises to an estimated 376,000 total deaths once SCD’s substantial indirect contribution to mortality (via infection, stroke, and organ failure) is accounted for, making it the 12th leading cause of death among children under five worldwide. Nearly 80% of this burden falls on sub-Saharan Africa, a region where access to disease-modifying and curative therapies remains, in practical terms, extremely limited.

SCD arises from a single point mutation in the β-globin gene (GAG→GTG at codon 6), first characterized biochemically by Ingram (1957) as the molecular basis of the electrophoretic difference Pauling and colleagues had identified between normal and sickle hemoglobin — historically one of the founding demonstrations that a specific human disease could be traced to a specific amino acid substitution in a specific protein. That substitution replaces glutamic acid with valine at the sixth position of the β-globin chain, creating a hydrophobic patch on the surface of deoxygenated hemoglobin S (HbS) that self-associates with a complementary hydrophobic acceptor pocket (centered on Phe85β and Leu88β) on adjacent HbS tetramers. Under conditions of deoxygenation, this interaction nucleates the polymerization of HbS into rigid, rod-like fibers that distort the erythrocyte into the characteristic sickle shape, producing vaso-occlusion, hemolysis, chronic anemia, and progressive multi-organ damage that define the clinical disease.

The modern targeted-therapeutics pipeline for SCD has, over the past decade, made real but strikingly fragile progress. Hydroxyurea, in clinical use since the 1990s, remains the therapeutic backbone: it induces fetal hemoglobin (HbF) production, which dilutes intracellular HbS concentration and directly interferes with polymerization, and it is inexpensive, oral, and broadly accessible — precisely the profile against which any new agent must be judged. L-glutamine (marketed as Endari) was approved in 2017 on an antioxidant/redox-modulation rationale. More recent rationally designed small molecules and biologics, however, have had a considerably rougher path to sustained clinical use. Voxelotor (Oxbryta), a small-molecule hemoglobin-oxygen-affinity modulator that covalently binds the N-terminal valine of the α-globin chain (Val1α) to stabilize the high-oxygen-affinity R-state and thereby inhibit polymerization, was approved in 2019 on the strength of surrogate hemoglobin-level endpoints — but was voluntarily withdrawn from every world market by Pfizer in September 2024 after post-marketing data indicated the drug’s benefit-risk balance was less favorable than initially understood, including signals of increased vaso-occlusive crisis and mortality risk in some populations. Crizanlizumab (Adakveo), a P-selectin-blocking monoclonal antibody targeting the adhesive, vaso-occlusive arm of SCD pathophysiology rather than HbS polymerization itself, had its European marketing authorization revoked by the European Commission in 2023 after its confirmatory phase III STAND trial failed to demonstrate efficacy over placebo. And while the two FDA-approved gene therapies — Casgevy (exagamglogene autotemcel, a CRISPR-Cas9-edited autologous cell therapy) and Lyfgenia (lovotibeglogene autotemcel, a lentiviral gene-addition therapy), both approved in December 2023 — offer a genuinely curative mechanism, their real-world uptake has been slow, constrained by list prices in the millions of dollars per patient, the need for myeloablative conditioning and specialized transplant-center infrastructure, and eligibility criteria that exclude the large majority of the global SCD population, concentrated as it is in precisely the low-resource settings least equipped to deliver such therapy.

This is the specific gap that motivates renewed scientific attention to natural product chemistry as an anti-sickling discovery axis. Unlike the synthetic small-molecule and biologic pipeline, natural anti-sickling remedies have a decades-long empirical use history in SCD-endemic regions, particularly West Africa, where the disease burden is highest and where a standardized polyherbal formulation — Niprisan, developed by Nigeria’s National Institute for Pharmaceutical Research and Development (NIPRD) and later licensed internationally as NIPRD-94/Nicosan — reached clinical evaluation and regulatory registration well before any of the synthetic agents discussed above existed. What has changed in the past five years, and what this review is specifically organized to capture, is the methodological sophistication with which this natural-product literature is now being interrogated: modern LC-MS phytochemical profiling, structure-based molecular docking against crystallographic hemoglobin targets, systematic ADMET (absorption, distribution, metabolism, excretion, toxicity) prediction, and an explicit engagement with the pharmacokinetic liabilities — poor oral bioavailability, rapid phase II conjugation, short plasma half-lives — that have historically limited many polyphenolic natural products’ translation from bench activity to clinical utility.

This review has four specific aims, each corresponding to a request this manuscript was explicitly commissioned to address. First, it synthesizes the molecular and structural pharmacology of SCD in sufficient detail to explain why particular natural-product chemical classes engage specific hemoglobin targets (Section 3). Second, it catalogs the natural product chemistry of anti-sickling agents — organized by chemical class and by botanical source — with particular attention to the mechanistic evidence linking each class to a specific point in HbS pathophysiology (Section 4). Third, and specifically because pharmacokinetic translatability is the single most common failure point for polyphenolic natural products generally, it provides a dedicated, compound-resolved treatment of the pharmacokinetics of the major natural anti-sickling chemotypes and the formulation strategies being used to address their ADME liabilities (Section 5). Fourth, it synthesizes — critically, not merely descriptively — the computational molecular docking literature that has emerged for natural-product-derived anti-sickling candidates, tabulating targets, methods, and binding-affinity results across the studies published to date, and using that synthesis to motivate a proposed integrated discovery pipeline for next-generation natural-product-derived anti-sickling agents (Section 6 and Section 7).

2. Review Methods and Scope

2.1. Literature Search Strategy

Literature was identified between June 2026 and August 2026 through structured searches combining terms from four intersecting domains: (i) sickle cell disease pathophysiology and pharmacology (“sickle hemoglobin polymerization,” “HbS,” “anti-sickling agent,” “voxelotor,” “hydroxyurea,” “gene therapy sickle cell”); (ii) natural product chemistry (“phytochemical,” “flavonoid,” “polyphenol,” “alkaloid,” “vanillin,” “Niprisan,” “NIPRD-94,” plus the binomial names of specific plant genera identified iteratively through citation-chasing); (iii) pharmacokinetics and ADME (“bioavailability,” “pharmacokinetics,” “ADME,” “ADMET,” “nanoformulation”); and (iv) computational chemistry (“molecular docking,” “AutoDock,” “PyRx,” “binding affinity,” “SwissADME”) combined with sickle-cell-specific terms. Sources were supplemented through manual citation chasing of key reviews (Garcia de Paula et al., 2024) and the reference lists of the identified primary docking studies (Asibor et al., 2024; Das, 2023).

2.2. Inclusion Criteria and Scope

Sources were retained if they (a) reported primary phytochemical, pharmacological, or clinical evidence of anti-sickling activity for a natural product or standardized natural-product formulation; (b) reported primary pharmacokinetic or ADME data for a natural anti-sickling compound or a close structural analog; (c) reported a computational molecular docking study using a natural-product ligand against a hemoglobin or hemoglobin-related target; or (d) were review articles synthesizing any of the above. Because this review’s docking discussion (Section 6) is explicitly a literature synthesis rather than a report of new computation — a scope decision made deliberately, and stated here transparently, because this review’s author did not have independent access to verified crystallographic coordinate data at the time of writing — every binding-affinity value, target structure, and software attribution reported in Section 6 is drawn directly from, and cited to, its original published or preprinted source; none is independently re-derived or estimated by this review’s author.

3. Molecular Pathophysiology of Sickle Cell Disease and Its Druggable Targets

3.1. The Val6Glu Mutation and HbS Polymerization

Adult human hemoglobin is a heterotetramer of two α- and two β-globin chains, each folded around a heme prosthetic group that reversibly binds molecular oxygen and undergoes the classic allosteric transition between a low-oxygen-affinity, deoxygenated tense (T) state and a high-oxygen-affinity, oxygenated relaxed (R) state. The GAG→GTG substitution at codon 6 of the β-globin gene replaces the negatively charged, hydrophilic glutamic acid at that position with the small, hydrophobic valine (Ingram, 1957) — a change with no functional consequence for oxygen binding itself, but with a profound consequence for the T-state tetramer’s surface chemistry. The mutant Val6β residue creates a hydrophobic protrusion on the surface of deoxygenated HbS that fits, with high geometric complementarity, into a hydrophobic acceptor pocket formed by Phe85β and Leu88β on the β-chain of a neighboring, symmetry-related HbS tetramer. Repeated engagement of this donor-acceptor interaction, once local HbS concentration and deoxygenation duration exceed a critical threshold, nucleates the formation of ordered, seven-stranded double helical fibers of polymerized HbS, which bundle into rigid rods that mechanically distort the erythrocyte membrane and cytoskeleton into the sickle shape.

This polymerization event is the proximate cause of essentially every downstream feature of SCD pathophysiology: sickled cells are rigid and adhesive, producing microvascular vaso-occlusion and the acute pain crises that are the disease’s clinical hallmark; repeated sickling and unsickling damages the erythrocyte membrane, producing chronic hemolytic anemia; and free heme and hemoglobin released by hemolysis scavenge nitric oxide and generate reactive oxygen species, driving a chronic vasculopathy that underlies the disease’s long-term organ damage (stroke, pulmonary hypertension, renal failure). This mechanistic cascade — mutation → hydrophobic self-association → polymerization → cellular sickling → vaso-occlusion/hemolysis → chronic vasculopathy — is what defines the specific, addressable molecular targets discussed in Section 3.2, and against which both synthetic and natural anti-sickling agents are ultimately evaluated.

3.2. Structural Targets for Pharmacological Intervention

Three structurally and mechanistically distinct classes of molecular target have emerged as the principal points of pharmacological intervention in HbS polymerization, and organizing the natural-product literature (Section 4) and the docking literature (Section 6) around this three-way taxonomy is, in the assessment of this review, essential to making sense of an otherwise heterogeneous body of work:

• The T-state polymerization interface — the Phe85β/Leu88β hydrophobic acceptor pocket and the Val6β donor contact itself — is the most direct target: an agent that binds within or adjacent to this interface can sterically or electrostatically block the donor-acceptor contact that nucleates fiber formation, without necessarily altering hemoglobin’s oxygen-binding equilibrium.
• The R-state Val1α allosteric pocket, occupied by the covalent hemoglobin-oxygen-affinity modulators typified by voxelotor and by the pyridyl-vanillin lineage of natural-product-inspired agents discussed in Section 4.2, is targeted indirectly: an agent that covalently or non-covalently stabilizes the R-state (high-oxygen-affinity) conformation increases hemoglobin’s affinity for oxygen, which reduces the fraction of time HbS spends deoxygenated in the microvasculature and thereby reduces the time available for polymerization to occur, without directly occluding the T-state polymerization interface itself.
• Oxidative and membrane-stabilizing targets are mechanistically indirect but clinically significant: because HbS polymerization and cyclic sickling generate substantial oxidative stress (through repeated membrane deformation, hemichrome formation, and heme-catalyzed reactive-oxygen-species production), agents that scavenge reactive oxygen species, chelate free iron, or stabilize the erythrocyte membrane and cytoskeleton can reduce hemolysis and secondary vasculopathy even without directly engaging the HbS polymerization interface — this is the mechanistic rationale most frequently invoked for the antioxidant polyphenol class reviewed in Section 4.1.

3.3. The Current Therapeutic Landscape and Its Limitations: Rationale for a Natural-Product Axis

Table 1 summarizes the current disease-modifying and curative therapeutic landscape for SCD against the three-target taxonomy of Section 3.2, and makes explicit the specific limitation — mechanistic, safety-related, or access-related — that motivates continued natural-product discovery work in each target category. Hydroxyurea remains the only agent in this landscape that is simultaneously effective, safe over decades of use, inexpensive, and orally administered — a combination that no synthetic small molecule or biologic approved since has matched, and that any natural-product candidate advancing toward clinical translation should be benchmarked against explicitly, not merely against placebo or against the withdrawn/revoked agents.

4. Natural Product Chemistry in Sickle Cell Disease: Classes and Mechanisms

Garcia de Paula et al. (2024), in the most comprehensive recent synthesis of this literature, note that anti-sickling activity across the natural product world is disproportionately concentrated among polar, oxygen-rich compounds — a pattern consistent with the T-state and oxidative targets of Section 3.2, both of which favor hydrogen-bonding and redox-active chemistry over the more purely hydrophobic engagement typical of many other natural-product bioactivity classes. This section organizes the field by chemical class, cross-referenced throughout to the specific plant sources from which each class’s leading anti-sickling representatives have been isolated.

4.1. Polyphenols and Flavonoids

Flavonoids — the largest and most extensively studied class of natural anti-sickling agents — recur across nearly every plant source discussed in this review. Quercetin, rutin (quercetin’s rhamnoglucoside), kaempferol and its glycosides, naringenin and its glycosides, and luteolin have each been reported, individually or as constituents of crude extracts, to inhibit HbS polymerization or promote sickled-cell reversal in vitro, generally through a combination of direct hemoglobin-surface binding (engaging the T-state polymerization interface of Section 3.2) and antioxidant radical scavenging (engaging the oxidative-target pathway). In the most recent and best-characterized computational evidence for this class, Asibor et al. (2024) identified luteolin as the single highest-affinity ligand across their entire screened phytochemical set against carbonmonoxy sickle hemoglobin (PDB 5E6E), with a docking score of −8.9 kcal/mol — appreciably stronger than the −7.4 kcal/mol scored by voxelotor as a co-docked reference standard in the same study (Section 6.2 provides the full comparative table). Elumba Ekutsu et al. (2024) report a parallel finding for two glycosylated flavonoids — naringenin-7-O-glucoside and kaempferol-3-O-glucoside, isolated from Uapaca heudelotii — both of which formed multiple hydrogen bonds with their docked hemoglobin target, with kaempferol-3-O-glucoside showing the stronger predicted interaction of the pair.

4.2. Phenolic Aldehydes: Vanillin and Its Pyridyl Derivatives

Vanillin — the simple phenolic aldehyde familiar as a food flavoring compound — occupies a distinctive position in this field’s history, because it is the natural-product-derived scaffold with the most rigorous structural and mechanistic characterization of any compound discussed in this review, and because its medicinal-chemistry evolution illustrates precisely the natural-product-to-optimized-derivative trajectory this review argues the wider field should pursue. Vanillin was first identified as a candidate anti-sickling agent for its capacity to increase hemoglobin’s oxygen affinity, and Abdulmalik et al. (2011) subsequently solved crystal structures of human hemoglobin in complex with a series of rationally designed pyridyl derivatives of vanillin, demonstrating directly that these compounds bind within the R-state Val1α allosteric pocket described in Section 3.2 — the identical pocket subsequently exploited by voxelotor — where they form a Schiff base with the N-terminal valine’s α-amino group, covalently stabilizing the high-oxygen-affinity R-state conformation. This crystallographic result is, to date, the single clearest structure-based confirmation in the entire natural-product-derived anti-sickling literature that a phytochemically-inspired scaffold engages the same validated target as an approved (if since withdrawn) synthetic drug, and it directly motivates this review’s proposal, developed further in Section 7.3, that pyridyl-vanillin derivatization is a template worth extending systematically to other natural phenolic aldehyde scaffolds.

A structurally related furan-based chemotype — 5-hydroxymethylfurfural (5-HMF) and its Michael-acceptor-modified furan-2-carboxaldehyde analogs — has followed a parallel medicinal-chemistry trajectory, engaging the same Val1α pocket through an analogous Schiff-base mechanism and motivating recent work on long-acting, covalently modified furan-carboxaldehyde hemoglobin modulators with dual (oxygen-affinity-increasing and direct anti-polymerization) antisickling activity. Together, the vanillin and furfural chemotypes constitute the best mechanistically validated natural-product-derived pharmacophore in the field, and stand in useful methodological contrast to the flavonoid class of Section 4.1, whose anti-sickling activity is comparatively well documented phenotypically but far less often confirmed at the structural (crystallographic) level.

4.3. Alkaloids

Alkaloids constitute a smaller but actively investigated class of natural anti-sickling candidates, with recent computational work specifically screening alkaloid libraries for anti-sickling potential in the broader context of hemoglobinopathy drug discovery. Mechanistically, alkaloid anti-sickling activity is generally attributed to direct hemoglobin binding at or near the T-state polymerization interface, though — as discussed critically in Section 6.4 — this attribution rests more heavily on computational docking prediction than on the crystallographic or biophysical confirmation available for the vanillin/furfural chemotype of Section 4.2, and should be treated as a promising but comparatively early-stage line of evidence.

4.4. Terpenoids and Other Chemical Classes

Terpenoid anti-sickling candidates have been reported from several of the plant sources discussed in Section 4.5 and Section 4.6, including a pentacyclic triterpene (acetyl-11-keto-β-boswellic acid) identified in the polyphenol-rich fraction of Detarium microcarpum alongside its flavonoid and phenolic-glycoside constituents (Idris Masa’ud et al., 2026). Fatty-acid derivatives (corchorifatty acid F, 2-hydroxyethyl octadecanoate) have been co-identified in the same fraction, though their contribution to anti-sickling activity relative to the fraction’s phenolic and flavonoid content remains uncharacterized — an example of the broader phytochemical-attribution problem discussed in Section 8, where crude and semi-purified plant extracts frequently show anti-sickling activity attributable, in aggregate LC-MS profiling, to several co-eluting compound classes at once.

4.5. Standardized Polyherbal Formulations: Niprisan and NIPRD-94

Niprisan (internationally developed and marketed as NIPRD-94/Nicosan) is the single most clinically advanced natural-product-derived anti-sickling formulation in the world, developed by Nigeria’s National Institute for Pharmaceutical Research and Development from a standardized combination of four plants — Cajanus cajan (pigeon pea) seed, Pterocarpus osun stem bark, Eugenia caryophyllum (clove) flower bud, and Sorghum bicolor leaf — following a rational reduction of a traditional polyherbal antisickling remedy to its most active fixed combination. Niprisan reached prophylactic clinical evaluation in SCD patients and was patented internationally, representing, for a period, one of the most advanced natural-product-to-clinic translation efforts in the entire SCD therapeutic landscape — a translation effort that ultimately stalled for manufacturing-standardization and commercial reasons rather than for lack of demonstrated activity, a cautionary case discussed further in Section 8. Directly relevant to the mechanistic classes of Section 4.1, Section 4.2 and Section 4.3, Asibor et al. (2024) computationally screened phytochemicals specifically drawn from the Niprisan plant panel — together with two additional Nigerian medicinal plants, Aframomum melegueta and Moringa lucida — against carbonmonoxy sickle hemoglobin, identifying luteolin (from within this panel) as their top-scoring ligand overall (Section 4.1, Section 6.2), providing a direct computational bridge between Niprisan’s decades of clinical use and the structure-based rationale increasingly available to explain it.

4.6. Other Medicinal Plants with Reported Antisickling Activity

Beyond the Niprisan panel, a broader set of African and pantropical medicinal plants has been investigated computationally and phytochemically for anti-sickling activity over 2023–2026. Zanthoxylum zanthoxyloides, long used in West African traditional antisickling remedies, yielded five phytochemical candidates in a PyRx-based docking screen against a Protein-Data-Bank-derived hemoglobin target, with the alkaloid-type compound fagaramide (and its trans-isomer) flagged as both a top docking hit and favorable on ADMET drug-likeness criteria (Das, 2023). Carica papaya (papaya) has an independent tradition of docking-based antisickling investigation. Detarium microcarpum (Fabaceae), a traditionally used West and Central African tree legume, was shown in the most recent (2026) evidence available for this review to reverse sickling in 70% of treated erythrocytes via its polyphenol-rich butanol leaf fraction — an effect comparable to the p-hydroxybenzoic-acid positive control used in that study — with LC-MS-based compound annotation identifying quercetin 3-galactoside and the phenolic glycoside citrusin C as leading candidate actives within the fraction (Idris Masa’ud et al., 2026). Uapaca heudelotii (Phyllanthaceae) yielded the naringenin- and kaempferol-glucoside pair discussed in Section 4.1 (Elumba Ekutsu et al., 2024). Table 2 consolidates these plant sources, their documented or predicted active constituents, and their primary chemical class, cross-referenced to the mechanistic taxonomy of Section 3.2.

5. Pharmacokinetic Considerations for Natural-Product-Derived Anti-Sickling Agents

A recurring weakness of the natural-product anti-sickling literature, evident across nearly every source reviewed in Section 4, is that in vitro anti-sickling or hemoglobin-binding activity is reported far more often than the pharmacokinetic data needed to judge whether that activity is achievable in vivo at a tolerable, orally deliverable dose. This section addresses that gap directly by reviewing the general ADME liabilities shared across the major natural anti-sickling chemotypes, the available compound-specific pharmacokinetic data, and the formulation and derivatization strategies being explored to overcome them.

5.1. General ADME Challenges of Polyphenolic Natural Products

Flavonoids and related polyphenols — the largest chemical class identified in Section 4.1 — share a well-characterized and largely unfavorable set of pharmacokinetic properties as a class. Most occur naturally as glycosides (sugar-conjugated forms) rather than as the free aglycone that typically shows the strongest direct hemoglobin-binding activity in vitro; oral absorption of the glycoside form generally requires either hydrolysis by intestinal or colonic microbial glycosidases to liberate the aglycone, or direct glycoside uptake by specific intestinal transporters, both of which are variable across individuals and substantially reduce and delay effective systemic exposure relative to the administered dose. Once absorbed, flavonoid aglycones undergo extensive first-pass phase II conjugation (glucuronidation and sulfation) in the intestinal wall and liver, such that the dominant circulating species in plasma is very often a conjugated metabolite rather than the pharmacologically characterized parent compound — a discrepancy that is frequently glossed over in the natural-product anti-sickling literature, where in vitro anti-sickling activity is reported for the parent aglycone without corresponding confirmation that the aglycone, rather than its conjugated metabolites, is what actually reaches red-cell hemoglobin systemically after oral dosing.

5.2. Compound-Specific Pharmacokinetic Data

Quercetin and rutin, the best pharmacokinetically characterized flavonoids in this review’s scope, illustrate this pattern quantitatively. Yang et al. (2005), in a direct comparative pharmacokinetic study in rats, reported that oral quercetin aglycone reaches substantially higher and faster plasma exposure than equimolar oral rutin, consistent with rutin’s requirement for microbial deglycosylation prior to absorption; independent human pharmacokinetic studies of quercetin glycosides corroborate that absolute oral bioavailability of flavonol glycosides in humans is low and highly formulation- and food-matrix-dependent. Genistein, the isoflavone most extensively characterized among the flavonoid subclass, shows a broadly similar profile: Yang, Kulkarni, Zhu, and Hu (2012), in a mechanistic ADME review, attribute genistein’s limited oral bioavailability principally to extensive intestinal and hepatic phase II conjugation rather than to poor intrinsic membrane permeability, identifying conjugation (not absorption) as the primary bioavailability-limiting step — a mechanistic distinction directly relevant to formulation strategy, because permeability-limited and metabolism-limited compounds respond to different pharmaceutical interventions (Section 5.3).

Curcumin, though not itself established as a direct anti-sickling agent in the sources reviewed in Section 4, is included here because it is the most extensively studied bioavailability-limited polyphenol in the pharmaceutical literature and because the nanoformulation strategies developed for it (Section 5.3) are the most mature template available for improving the pharmacokinetics of the structurally related flavonoid anti-sickling candidates of Section 4.1. Curcumin’s oral bioavailability in unformulated form is very low, driven by a combination of poor aqueous solubility, rapid intestinal and hepatic metabolism, and rapid systemic elimination — a combination severe enough that curcumin has become something of a cautionary benchmark case in the natural-product pharmacology literature for the gap between potent in vitro activity and achievable in vivo exposure.

The vanillin/pyridyl-vanillin chemotype of Section 4.2 occupies a pharmacokinetically distinct position within this review’s scope, precisely because — unlike the flavonoid class — its lead optimization was explicitly structure-guided from the outset (Abdulmalik et al., 2011), with pyridyl substitution patterns selected in part to modulate the covalent Schiff-base reaction kinetics with the target Val1α residue and thereby to tune the compound’s effective duration of hemoglobin engagement, rather than relying solely on non-covalent binding affinity. This is a materially different pharmacokinetic design philosophy from the flavonoid class’s largely natural, unmodified-aglycone approach, and it is the principal reason this review identifies the vanillin/furfural chemotype (Section 4.2) as the most translationally advanced natural-product-derived lineage discussed here.

5.3. Strategies to Enhance Natural-Product Pharmacokinetics

Three complementary strategies recur throughout the broader polyphenol pharmacokinetics literature and are directly applicable to the natural anti-sickling chemotypes in Section 4. First, nanoformulation — encapsulation in liposomes, polymeric or lipid nanoparticles, or complexation with cyclodextrins or phospholipids — has been shown extensively for curcumin to substantially improve aqueous solubility, protect the compound from rapid first-pass metabolism, and prolong systemic exposure; Yallapu, Bhusetty Nagesh, Jaggi, and Chauhan (2015), in a comprehensive review of curcumin nanoformulations, catalogue this strategy’s application across drug-delivery contexts and its consistent capacity to improve on unformulated curcumin’s poor pharmacokinetic profile, providing a directly transferable template for the flavonoid anti-sickling candidates of Section 4.1, none of which, to this review’s knowledge, has yet been evaluated in nanoformulated form specifically for anti-sickling pharmacokinetics. Second, targeted chemical derivatization — exemplified by the pyridyl-vanillin lineage in Section 4.2 — can simultaneously improve target engagement and modulate metabolic stability, illustrating that natural-product optimization need not be limited to formulation-based delivery strategies. Third, standardized polyherbal combination, the strategy underlying Niprisan (Section 4.5), offers a distinct rationale: rather than optimizing a single compound’s pharmacokinetics, a fixed multi-plant combination may achieve therapeutically meaningful systemic exposure through the combined, potentially synergistic contribution of several moderately bioavailable constituents acting on complementary targets (Section 3.2) simultaneously — though, as discussed in Section 8, this combinatorial rationale has historically been easier to achieve empirically than to characterize pharmacokinetically with the compound-resolved rigor now expected of a modern therapeutic development program.

5.4. Pharmacokinetics as a Design Constraint for Next-Generation Agents

Taken together, Section 5.1, Section 5.2 and Section 5.3 support a specific methodological recommendation, developed further in Section 7: pharmacokinetic characterization — at minimum, in silico ADMET prediction of absorption, metabolic stability, and plasma half-life (Section 6.1), and ideally in vivo confirmatory pharmacokinetic data of the type available for quercetin, rutin, and genistein (Section 5.2) — should be treated as a mandatory, not optional, companion to any newly reported anti-sickling docking or in vitro activity result for a natural-product candidate. A substantial fraction of the docking literature synthesized in Section 6 reports ADMET prediction alongside binding-affinity results, which this review regards as good and increasingly standard practice; the gap that remains, identified as a priority in Section 8, is the comparative scarcity of in vivo pharmacokinetic confirmation for any lead beyond the vanillin/furfural chemotype and the small set of individually well-studied flavonoids (quercetin, rutin, genistein) discussed above.

6. Computational Docking Studies of Natural Products Against Sickle Hemoglobin Targets: A Literature Synthesis

Molecular docking — the computational prediction of a small molecule’s preferred binding pose and relative binding affinity within a target protein’s structure — has become, over 2023–2026, the dominant first-pass screening method by which the natural anti-sickling candidates of Section 4 are being triaged and prioritized for further study. This section synthesizes that literature critically: it tabulates the specific targets, software, and quantitative binding-affinity results reported to date (Section 6.2), relates those computational predictions back to the structural biology of Section 3.2 (Section 6.3), and closes with an explicit methodological appraisal of the literature’s current limitations (Section 6.4) — an appraisal this review considers as scientifically necessary as the synthesis itself, given how easily a docking score can be over-interpreted as a demonstrated biological result rather than a triage-stage computational prediction.

6.1. Structural Targets and Standard Computational Workflow

The docking studies reviewed here converge on a broadly consistent computational workflow, even though they vary in the specific target structure and software used. Target selection has centered on crystallographic hemoglobin structures deposited in the Protein Data Bank: Asibor et al. (2024) used the carbonmonoxy sickle hemoglobin R-state structure (PDB 5E6E) as their receptor, explicitly chosen to allow direct co-docking comparison against voxelotor, itself an R-state (Val1α-pocket) binder (Section 3.2); Das (2023) and the Carica papaya docking literature draw their hemoglobin receptor structures more generally from the Protein Data Bank without specifying the R-state/T-state distinction as precisely. Ligand libraries are drawn from the phytochemical constituents of the plant sources catalogued in Section 4 (identified via prior phytochemical screening or LC-MS annotation, as in Idris Masa’ud et al., 2026), prepared computationally, and docked using PyRx — an open-source virtual-screening front end for AutoDock Vina — the software platform reported across the majority of studies synthesized here (Das, 2023; and, per this review’s reading of the available reporting, Asibor et al., 2024), often paired with Discovery Studio for pose visualization and interaction analysis. Downstream ADMET filtering is typically performed using SwissADME or comparable in silico prediction tools, applied to shortlist docking hits on drug-likeness and predicted pharmacokinetic criteria before any compound is prioritized for the in vitro or in vivo follow-up work discussed in Section 4 and Section 5.

6.2. Synthesis of Reported Binding-Affinity Results

Table 3 consolidates the quantitative binding-affinity results reported across the docking studies synthesized in this review, standardized to kcal/mol (AutoDock Vina’s native scoring output) where reported, and including, where available, the study’s own co-docked reference standard. The single most information-dense result in this table is Asibor et al.’s (2024) direct comparison of luteolin (−8.9 kcal/mol) and phenanthrene-5,6-dione (−8.3 kcal/mol) against co-docked voxelotor (−7.4 kcal/mol) within the same computational study — a rare instance in this literature of a natural-product ligand being benchmarked, within a single consistent docking protocol, against the strongest available synthetic comparator, and one that (with the significant caveat discussed in Section 6.4 that a more favorable docking score does not by itself establish superior real-world efficacy, safety, or pharmacokinetics) provides the field’s best current computational evidence that specific natural flavonoids may engage the R-state Val1α pocket at least as tightly as voxelotor did before its 2024 withdrawal.

6.3. Structural Rationale: Correlating Docking Poses with Known Reactive Residues

The strongest structural anchor available for interpreting this docking literature remains the crystallographic result of Abdulmalik et al. (2011): because pyridyl-vanillin derivatives are directly shown, by X-ray crystallography rather than by docking prediction, to occupy the R-state Val1α pocket and form a covalent Schiff base with the N-terminal α-amino group, any subsequently docked natural-product ligand — including luteolin and phenanthrene-5,6-dione (Section 6.2) — that is predicted to bind at or near this same pocket carries substantially more structural credibility than a ligand predicted to bind at a generic, unvalidated surface site. Conversely, the T-state Phe85β/Leu88β polymerization interface (Section 3.2), while mechanistically the most direct anti-sickling target, has comparatively little crystallographic natural-product-bound precedent in the literature synthesized here, meaning that docking predictions targeting this interface specifically — where reported — currently rest on a thinner structural validation base than those targeting the Val1α pocket.

6.4. Critical Appraisal: Methodological Limitations of the Existing Docking Literature

This review’s synthesis in Section 6.1, Section 6.2 and Section 6.3 should not be read as an endorsement of the evidentiary strength of the current docking literature, and this subsection explicitly states what that literature does not yet establish. First, virtually all of the docking studies synthesized here use rigid or near-rigid receptor docking (standard for PyRx/AutoDock Vina-based virtual screening), which does not capture receptor conformational flexibility or the induced-fit binding behavior that can materially affect real binding affinity, particularly for a protein like hemoglobin whose entire biological function depends on a large-scale allosteric conformational transition (Section 3.1) — a limitation that applies with particular force to any T-state-targeted docking prediction, given that hemoglobin’s T-to-R transition is precisely the conformational change most docking protocols in this literature do not model dynamically. Second, few of the studies synthesized here report redocking validation against a co-crystallized reference ligand to confirm that their docking protocol reproduces a known experimental binding pose before applying it to novel natural-product ligands — a standard methodological control in rigorous structure-based virtual screening that this review recommends explicitly as a minimum bar for future work in this specific field (Section 8). Third, only Asibor et al. (2024), among the studies synthesized here, reports a co-docked reference standard (voxelotor) within the same protocol, which is what makes cross-study comparison of binding-affinity values across the remaining literature difficult to interpret quantitatively — a −8.3 kcal/mol score in one study and a −7.9 kcal/mol score in a different study using a different target structure and software are not directly comparable numbers, even though both may be reported using the same units. Fourth, and most fundamentally, a favorable docking score is, at best, a triage-stage hypothesis-generating result: none of the docking studies synthesized in this section report corresponding experimental validation (isothermal titration calorimetry, surface plasmon resonance, or a direct hemoglobin-polymerization-inhibition assay conducted on the specific docked compound) confirming that the predicted binding pose or affinity is reproduced experimentally — a gap this review identifies, in Section 8, as the single highest-priority next step for the computational side of this field.

7. Toward Next-Generation Natural-Product-Derived Anti-Sickling Agents

7.1. Structure-Activity Patterns Emerging Across Chemical Classes

Reading Section 4 through 6 together, a structure-activity pattern emerges that this review believes is worth stating explicitly, because it has not, to this review’s knowledge, been articulated as a unifying design principle elsewhere in the literature synthesized here. The natural anti-sickling chemotype with the strongest mechanistic and structural validation — the vanillin/pyridyl-vanillin/furfural lineage of Section 4.2 — is also the chemotype whose members are small, planar, aldehyde-bearing phenolics capable of forming a covalent Schiff base with a primary amine (the Val1α N-terminal amino group). The flavonoid class of Section 4.1, by contrast, is structurally larger, non-covalent, and polyhydroxylated, and its members’ anti-sickling activity is comparatively better explained by a combination of hydrogen-bonding surface engagement and antioxidant radical scavenging than by a single, structurally defined covalent mechanism. This suggests that natural-product anti-sickling chemical space may be usefully organized along a covalent-mechanistic axis (small aldehyde-bearing phenolics, exemplified by vanillin/furfural, acting via covalent Val1α engagement) crossed with a non-covalent-antioxidant axis (larger polyhydroxylated flavonoids, acting via combined T-state surface binding and radical scavenging) — a two-axis framework that could, in principle, guide rational selection of which natural scaffolds to prioritize for which specific therapeutic objective (rapid, durable oxygen-affinity modulation versus broader anti-polymerization/antioxidant activity).

7.2. A proposed Integrated Discovery Pipeline

Synthesizing the methodological strengths and gaps identified across Section 4, Section 5 and Section 6, this review proposes the following integrated discovery pipeline for advancing natural-product anti-sickling leads, sequenced so that inexpensive computational and in vitro triage steps precede the more resource-intensive pharmacokinetic and structural confirmation steps:

• Step 1 — Phytochemical extraction and LC-MS/NMR-based compound annotation of candidate plant material, following the standard established by Idris Masa’ud et al. (2026) for Detarium microcarpum, to move beyond crude-extract activity toward compound-resolved candidate identification.
• Step 2 — In vitro anti-sickling assay (erythrocyte sickling-reversal or HbS polymerization-inhibition assay) on isolated or semi-purified fractions, to confirm that activity attributed to a candidate compound class is retained outside the full crude-extract matrix.
• Step 3 — Structure-based molecular docking against both R-state (Val1α-pocket) and T-state (Phe85β/Leu88β-interface) hemoglobin structures, with mandatory redocking validation against a co-crystallized reference ligand and mandatory co-docking of a known standard (voxelotor or a pyridyl-vanillin derivative) within the same protocol — directly addressing the cross-study comparability gap identified in Section 6.4.
• Step 4 — In silico ADMET prediction (SwissADME or equivalent) applied jointly with the docking triage of Step 3, to eliminate candidates with poor predicted drug-likeness or metabolic stability before committing to synthesis or purification effort — the practice already followed by several studies synthesized in Section 6, generalized here as a mandatory rather than optional pipeline stage.
• Step 5 — Compound-resolved in vivo pharmacokinetic characterization (at minimum in a rodent model) for any candidate advancing past Steps 1–4, explicitly addressing the bioavailability, conjugative-metabolism, and half-life questions raised in Section 5, rather than proceeding directly from in vitro/docking activity to formulation or clinical development.
• Step 6 — Targeted derivatization or nanoformulation (Section 5.3), informed by which pharmacokinetic liability Step 5 identifies as rate-limiting (poor absorption versus rapid conjugative metabolism), applying the structure-guided derivatization template of the pyridyl-vanillin lineage (Section 4.2) where a covalent Val1α mechanism is being optimized, or the nanoformulation template of curcumin (Section 5.3) where a non-covalent flavonoid mechanism is being optimized.

7.3. A worked Design Example: Pyridyl-Vanillin as a Derivatization Template

To make Section 7.2’s pipeline concrete, consider how it would apply to a newly identified flavonoid hit — for instance, luteolin, the top-scoring ligand identified computationally by Asibor et al. (2024, Section 6.2). Under the two-axis framework of Section 7.1, luteolin’s polyhydroxylated, non-covalent binding mode places it on the antioxidant/T-state-engagement axis rather than the covalent Val1α axis exploited by pyridyl-vanillin. A rational next step, following Step 6 of the proposed pipeline, would not be to attempt to force a covalent Val1α mechanism onto luteolin’s scaffold — a chemically unnatural fit — but rather to pursue the nanoformulation route already validated for structurally related flavonoids in the curcumin literature (Section 5.3), while separately and independently pursuing pyridyl- or furyl-type derivatization on a distinct, aldehyde-bearing natural scaffold better suited mechanistically to that covalent chemistry, such as a phenolic aldehyde isolated from one of the plant sources in Table 2 rather than a flavonoid. This worked example illustrates the central methodological point of Section 7.1: matching the optimization strategy to the mechanistic class, rather than applying a single one-size-fits-all derivatization or formulation approach across structurally and mechanistically distinct natural-product chemotypes, is what this review argues should distinguish a genuinely next-generation natural-product-derived anti-sickling discovery program from the largely single-compound, single-method studies that currently dominate the literature synthesized in Section 6.

8. Current Gaps and Challenges

• Gap 1 — Sparse experimental validation of docking predictions. As detailed in Section 6.4, none of the docking studies synthesized in this review report direct biophysical (ITC/SPR) or functional (polymerization-inhibition assay) confirmation of their top computational hits against the specific docked target — the single highest-priority gap identified in this review.
• Gap 2 — Inconsistent target structures and lack of redocking validation across studies, which — as discussed in Section 6.4 — makes binding-affinity values non-comparable across the literature and undermines confidence in cross-study ranking of candidate compounds.
• Gap 3 — Compound-attribution ambiguity in crude and semi-purified extracts. Several of the plant sources reviewed in Section 4.6 (e.g., Detarium microcarpum) show confirmed anti-sickling activity in a multi-compound fraction without fully resolved attribution of that activity to a single constituent, complicating both mechanistic interpretation and downstream derivatization efforts (Section 7).
• Gap 4 — Near-total absence of in vivo pharmacokinetic data for the leading flavonoid and alkaloid natural anti-sickling candidates, beyond the general (non-SCD-specific) flavonoid PK literature reviewed in Section 5.2 — the specific gap Section 5.4 identifies as a mandatory pipeline stage going forward.
• Gap 5 — Stalled translation of the field’s most clinically advanced candidate. Niprisan/NIPRD-94 (Section 4.5) reached international patenting and prophylactic clinical evaluation but has not achieved sustained, broadly available clinical use, for reasons this review’s sources attribute principally to manufacturing standardization and commercial/regulatory factors rather than to a demonstrated lack of efficacy — a cautionary precedent for any natural-product candidate advancing through the pipeline proposed in Section 7.2, underscoring that scientific and computational validation alone (Section 4, Section 5 and Section 6) is necessary but not sufficient for durable clinical translation.
• Gap 6 — No published study in this review’s scope directly compares a natural-product anti-sickling candidate against hydroxyurea — the actual standard-of-care benchmark identified in Section 3.3 — under a matched experimental protocol; nearly all comparative benchmarking in the literature synthesized here (Section 6.2) is against voxelotor, a withdrawn drug, rather than against the therapy patients are most likely to already be receiving.

9. Future Directions

By directly addressing the six gaps in Section 8, this review recommends the following priorities for the field. First (closing Gap 1 and Gap 2), future docking studies in this space should adopt the redocking-validation and co-docked-reference-standard practices modeled by Asibor et al. (2024) as a minimum reporting standard, and should, wherever feasible, pair computational hits with at least one direct biophysical or functional confirmation assay before a compound is described as a validated lead rather than a computational hit. Second (closing Gap 3), LC-MS/NMR-based compound-resolved phytochemical annotation, of the type demonstrated by Idris Masa’ud et al. (2026), should be treated as a prerequisite for, not an optional supplement to, reporting anti-sickling activity for any crude or semi-purified natural extract. Third (closing Gap 4), in vivo pharmacokinetic characterization — even a single-dose rodent study — should be incorporated substantially earlier in the discovery pipeline than is current practice, following Step 5 of the pipeline proposed in Section 7.2, rather than being deferred until after extensive structure-activity optimization has already been completed on a scaffold whose pharmacokinetic viability has not yet been established. Fourth (closing Gap 5), any natural-product candidate advancing toward clinical translation should engage manufacturing-standardization and regulatory strategy from an early stage, drawing explicitly on the documented history of the Niprisan/NIPRD-94 program (Section 4.5, Section 8) as a source of lessons learned rather than treating standardization as a downstream, purely logistical concern. Fifth (closing Gap 6), future comparative studies — computational and experimental alike — should include hydroxyurea as a benchmark comparator alongside or instead of voxelotor, given hydroxyurea’s status as the actual therapy most SCD patients receive and the specific, safety- and efficacy-driven reasons (Section 3.3) that voxelotor and crizanlizumab are no longer appropriate benchmarks of clinical success.

More broadly, this review closes by observing that the natural-product anti-sickling literature is, in 2026, in a methodologically transitional moment: the phytochemical and ethnopharmacological foundation is decades deep and geographically concentrated exactly where the disease burden is highest (Section 1), the computational triage tools needed to prioritize within that foundation are now widely accessible and increasingly well used (Section 6), and the specific structural precedent needed to guide rational optimization — the pyridyl-vanillin Val1α-pocket crystal structures of Abdulmalik et al. (2011) — has existed for over a decade without, to this review’s knowledge, being systematically extended to the wider flavonoid and alkaloid natural-product space reviewed in Section 4.1 and Section 4.3. Closing that specific gap — applying validated, structure-based medicinal-chemistry rigor to the broader natural anti-sickling chemical space, with pharmacokinetics designed in from the outset rather than assessed as an afterthought — is, in the assessment of this review, the most direct and currently most tractable path from the extensive natural-product evidence synthesized here to a genuinely next-generation, natural-product-derived anti-sickling therapeutic.

10. Conclusion

This review has synthesized the natural product chemistry, pharmacokinetics, and computational docking literature bearing on sickle cell disease at a moment when the synthetic and biologic therapeutic pipeline has suffered three consecutive, high-profile setbacks — the 2024 worldwide withdrawal of voxelotor, the 2023 European revocation of crizanlizumab’s marketing authorization, and the persistently slow, cost-limited uptake of the Casgevy and Lyfgenia gene therapies — that collectively underscore why a scientifically rigorous natural-product discovery axis, rooted in the decades-long empirical use history concentrated in the highest-burden regions of the world, deserves renewed and methodologically modernized attention. The evidence reviewed here establishes that specific natural-product chemotypes — most concretely the crystallographically validated pyridyl-vanillin/furfural lineage, and most promisingly the computationally prioritized flavonoid lineage typified by luteolin — engage the same validated structural targets as the synthetic agents discussed in Section 3, in at least one direct computational comparison scoring more favorably than voxelotor itself (Section 6.2). At the same time, this review has been explicit that the field’s computational docking literature currently lacks the experimental validation, cross-study standardization, and hydroxyurea-benchmarked comparison needed to translate a favorable binding-affinity score into a genuine therapeutic candidate (Section 6.4, Section 8), and that pharmacokinetic characterization — the dimension this review was specifically commissioned to address — remains the single most underdeveloped link between promising in vitro/in silico activity and any realistic path to oral, clinically deployable natural-product-derived anti-sickling therapy (Section 5). The integrated discovery pipeline and structure-activity framework proposed in Section 7 are offered as a concrete, actionable response to these specific, named gaps — and as a scientific case that natural product chemistry, pursued with the same structural, pharmacokinetic, and computational rigor now standard in synthetic medicinal chemistry, remains one of the most promising and, given the geography of disease burden and cost of the current alternatives, most urgently needed directions in sickle cell disease therapeutics today.